MEDICINOVA, INC.

MediciNova to Present at American Academy of Emergency Medicine Annual Meeting

Mid-day Movers (THLD, OPTT, ZNGA, MNOV, MNKD)

MedicNova falls 14.6%

24/7 Wall St. Closing Bell (DELL, EW, AKS, STLD, BRCM, GMCR, EDMC, NDAQ, QCOM, BZH, BSX, BCO, DO, LEA, MRK, TTWO, VIAB, ZNGA, MNOV, RGDX, BIOS, URG)

Mid-day Movers (VRNG, MNOV, ZNGA, BCO, ANF)

MedicNova rises 33.3%

MedicNova rises 29.6%

MedicNova receives notice of patent allowance for a method of treating MS

MediciNova and University of Colorado Boulder Collaborate on Potential Novel Therapy for Traumatic

MedicNova and UC Boulder collaborate on brain injury therapy

MediciNova and University of Colorado Boulder Collaborate on Potential Novel Therapy for Traumatic Brain Injury

MediciNova and University of Colorado Boulder Collaborate on Potential Novel Therapy for Traumatic Brain Injury

MediciNova - Breathing Easy

MediciNova, Inc. Appoints Kousuke Nakata to Its Board of Directors

MediciNova, Inc. Appoints Kousuke Nakata to Its Board of Directors

MedicNova reports Q3 EPS (25c) vs. consensus (29c)

MediciNova Reports Third Quarter 2011 Results

MediciNova Reports Third Quarter 2011 Results

Synteract and MediciNova Partner in "Fight For Air Walk" to Support the American Lung Association in California

Synteract and MediciNova Partner in "Fight For Air Walk" to Support the American Lung Association in California

MediciNova to Present at the Lazard Capital Markets Healthcare Conference

MediciNova to Present at the Lazard Capital Markets Healthcare Conference

MedicNova announces repeat dose clinical trial with MN-221

MediciNova Announces Repeat Dose Clinical Trial With MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

MediciNova Announces Repeat Dose Clinical Trial With MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

MediciNova, Inc. to Receive $2.5 Million Payment From Kissei Pharmaceutical Co., Ltd. to Expand Clinical Development of the MN-221 Program

MedicNova receives $2.5M payment from Kissei Pharma to expand MN-221 program

MediciNova to Receive $2.5 Million Payment From Kissei Pharmaceutical Co. Ltd. to Expand Clinical Development of the MN-221 Program

MedicNova closes $7.5M private stock sale to Kissei Pharmaceuticals

MediciNova Closes $7.5 Million Private Stock Sale to Kissei Pharmaceutical Co., Ltd.

MediciNova Closes $7.5 Million Private Stock Sale to Kissei Pharmaceutical Co., Ltd.

Kissei purchase of MediciNova stock funds ex-Kissei asthma/COPD candidate

MedicNova announces private sale of stock to Kissei Pharmaceutical

MediciNova, Inc. Announces Private Sale of Stock to Kissei Pharmaceutical Co., Ltd.

MediciNova, Inc. Announces Private Sale of Stock to Kissei Pharmaceutical Co., Ltd.

MediciNova, Inc. Appoints Mr. Tatsuo Izumi to Its Board of Directors

MediciNova, Inc. Appoints Mr. Tatsuo Izumi to Its Board of Directors

Diabetic Neuropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

MediciNova (MNOV) Appoints New CMO and CFO

MediciNova Announces Management Appointments